EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer

2019-09-01
Asik, Elif
Akpinar, Yeliz
Caner, Ayse
Kahraman, Nermin
Güray, Nülüfer Tülün
Volkan, Mürvet
Albarracins, Constance
Pataer, Apar
Arun, Banu
Ozpolat, Bulent
Aim: To investigate the role of EF2K in BRCA1-mutated breast cancer. Materials & methods: We developed silica coated cobalt-ferrite (CoFe) nanoparticles for in vivo delivery of small interfering RNAs (siRNAs) into BRCA1-mutated breast cancer. Results: Expression of EF2K is highly upregulated in themajority (78.5%) of BRCA1-mutated patients and significantly associated with poor patient survival and metastasis. Silencing of EF2K reduced cell proliferation, migration and invasion of the cancer cells. In vivo therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained EF2K gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer. Conclusion: EF2K is a potential novel molecular target in BRCA1-mutated tumors and CoFe-based siRNA nanotherapy may be used as a novel approach to target EF2K.

Citation Formats
E. Asik et al., “EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer,” NANOMEDICINE, vol. 14, no. 17, pp. 2315–2338, 2019, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/37857.